This program will expand research and policy development to overcome androgen misuse (off label testosterone prescribing for invalid indications) and combat androgen ('anabolic steroid') abuse for performance and image enhancement. Beyond expanding ongoing research, it will develop a new focus in developing drugs to accelerate recovery from androgen abuse, thereby preventing relapse during the slow natural recovery period typically lasting 6-18 months or longer
A Phase III Randomised Placebo-controlled Trial Of Mirtazapine As A Pharmacotherapy For Methamphetamine (Ice) Dependence
Funder
National Health and Medical Research Council
Funding Amount
$3,923,009.00
Summary
Crystalline methamphetamine ('ice') is a growing concern in Australia. There are no approved medications that can be used to treat dependence on this drug. This clinical trial will examine whether mirtazapine, a newly identified treatment agent for methamphetamine use, can be used safely and effectively in routine clinical care to manage methamphetamine dependence in Australia.